Drug Research
AVI BioPharma starts patient dosing in DMG drug Phase 2 trial
AVI BioPharma has started patient dosing in a placebo-controlled Phase 2 trial to evaluate eteplirsen as a treatment for Duchenne muscular dystrophy (DMD).The study intends to investigate the safety and efficacy of eteplirsen in DMD patients over 24 weeks...
Drug Research
Biogen Idec, Abbott release Select Phase 2b RRMS drug trial results
Biogen Idec and Abbott have released top-line results from a double-blind, dose-ranging, randomized and placebo-controlled Select Phase 2b trial evaluating the experimental compound daclizumab high-yield process (DAC HYP) in patients with relapsing-remitting multiple sclerosis (RRMS) over one year. ...
Drug Research
Innovacyn introduces eye, ear formulations
Innovacyn, a provider of human and animal healthcare products, has added Vetericyn VF Ophthalmic Wash and Vetericyn VF Otic Rinse to its professional-strength animal healthcare line. The antimicrobial solution found in the Ophthalmic Wash and Otic...
Drug Research
Glenmark settles patent case with Daiichi, Genzyme
Glenmark Pharmaceuticals has settled patent litigation suit with Daiichi Sankyo and Genzyme in relation to its type-2 diabetes treatment Colesevelam Hydrochloride’s abbreviated new drug application (ANDA). With this settlement, Glenmark can roll out its generic...
Drug Research
RxMD signs drug development agreement with GlycoRegImmune
RxMD has collaborated with GlycoRegImmune (GRI) to develop new treatments by using GRI's novel natural killer (NK) T cell targeted technologies for autoimmune, inflammatory and neurodegenerative conditions. As per the terms of the agreement, RxMD will...
Drug Research
Evotec, Roche collaborate to develop oncology biomarkers
Evotec has entered into an oncology research and development agreement with Roche to organize multiple protein-activity based biomarker programs for Roche's therapeutic antibodies or small molecule inhibitors under development. Under the agreement, Evotec will use...
Drug Research
Evotec and PsychoGenics Enter into a Strategic Alliance to Provide Integrated CNS Drug Discovery Solutions
Evotec AG announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies. The two companies will work together in a seamless fashion to provide existing...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read